Offers Oncologists Comprehensive Profiling Solutions to Optimize Therapeutic Decision-Making for Cancer Patients


Lewisville, Texas, November 30, 2015 – med fusion, an integrated Molecular Center of Excellence and clinical trials service organization, announced the expansion of its molecular diagnostic testing services to include the Oncotype DX® assays which are available to oncologists nationwide. These multi-gene tests can help physicians make individual treatment decisions for their cancer patients by identifying which invasive breast cancer patients may likely benefit from chemotherapy as well as assessing recurrence risk in Ductal Carcinoma In Situ (DCIS), colon and prostate cancers.


med fusion’s molecular diagnostic test menu is comprised of disease-specific panels and one 50-gene solid tumor panel powered by Next Generation Sequencing for navigating within standard of care therapies, clinical trial treatment and outside standard of care options. The 50-gene panel (called 50SEQ) is for rare, refractory diseases where standard of care options have already been exhausted and clinical trials are under consideration. Individual biomarkers are also offered to provide physicians with further information when developing a treatment plan.


Genomic Health’s Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. These tests provide patients with a risk category and a numerical score to assess the probability that cancer patients will see a recurrence of the disease. The Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS.


“med fusion is committed to being a market leader in providing responsible molecular testing in a patient-centric way, and we are very excited to be partnering with Genomic Health in this regard,” says Jon Hart, CEO of med fusion. “Our collaboration with Genomic Health supports med fusion’s model of creating and developing strategic relationships that complement our offering of personalized diagnostic testing services within a patient focused and supportive model of care delivery.”


med fusion and Genomic Health share a common vision of advancing the delivery of high-quality precision medicine and molecular diagnostic services for patients with cancer. med fusion and Genomic Health entered into an agreement which enables an easier ordering process for med fusion medical oncology clients to receive the Oncotype DX tests for their patients. Oncologists will be able to order the tests through their pathology services directly from med fusion.


About med fusion


med fusion, an integrated Molecular Center of Excellence and clinical trials service organization, delivers support to healthcare providers and biotech/pharmaceutical companies to consistently meet the needs of patients. An industry leader in advanced laboratory diagnostics and support, our full service clinical laboratory includes a dedicated test development and validation team to meet the needs of clients and reference lab services such as pathology and molecular diagnostics. med fusion is committed to facilitate the realization of personalized medicine by specializing in: Oncology, Women’s Health, Urology, and Infectious Disease. Headquartered in Lewisville, Texas, med fusion offers its specialized services throughout the U.S. To learn more, please visit www.medfusionservices.com.


###


Media Contact:
Sherry Macurak,
smacurak@medfusionsvs.com
972-966-7000